News

Sarepta Therapeutics: Beaten Down, But Not Out
Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.
Business Wire12h
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...
Fierce Biotech9h
Arrowhead says beleaguered Sarepta has 60 days to pay $100M in milestone
Arrowhead said it has met both of these conditions in a July 28 release and now expects to receive the $100 million within 60 days. The company also said it plans on reaching the second enrollment ...
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics
Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone ...
Healthcare earnings: UnitedHealth delays, Sarepta's FDA probe
UnitedHealth (UNH) delayed its earnings report amid rising medical costs and is now set to report second quarter results on ...
Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained.
Sarepta Therapeutics stock was sliding again on Monday, as investors struggled to make sense of further bad news concerning ...
Sarepta rises 2%; Barclays downgrades to underweight on liquidity and Elevidys concerns
Sarepta Therapeutics (SRPT) shares dropped sharply on Monday following news that the FDA is investigating a patient death potentially connected to its gene therapy, Elevidys.
BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO ...